The women’s health company Organon has put forward the first real-world data collected from its Jada system, a device used to help stop excessive and potentially life-threatening bleeding following ...

Organon & Co. OGN announced the completion of the divestiture of its JADA System to Laborie Medical Technologies Corp. The deal is worth up to $465 million, including $440 million paid at closing and ...

Please provide your email address to receive an email when new articles are posted on . The JADA system decreased abnormal postpartum uterine bleeding in vaginal and cesarean birth, regardless of ...

The JADA® System for treatment of abnormal postpartum uterine bleeding, and the team behind the product, join Laborie, strengthening the company's commitment to improving maternal health. Joining an ...

Laborie Medical Technologies Corp. secured a new gem for its maternal health with the acquisition of the Jada system from Organon & Co. The terms of the deal, first announced in November, included ...

Investor AB ( ($SE:INVE.A) ) has shared an announcement. Patricia Industries’ subsidiary, Laborie, is set to acquire the JADA System from Organon, a medical device ...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global women’s health company, today announced clearance by the U.S. Food and Drug Administration (FDA) of the Special 510(k) for ...

Please provide your email address to receive an email when new articles are posted on . Treatment success for the JADA system was high for both vaginal and cesarean births. Overall, 2.8% of women in ...

Organon is selling its JADA post-partum haemorrhage (PPH) treatment system to Laborie Medical in a deal valued at up to $465m. The US-based company will receive $440m at the deal’s closing, with ...

Organon, a global healthcare company focused on improving women’s health, today announced that Obstetrics & Gynecology (“The Green Journal”), the peer-reviewed journal of the American College of ...